Rosetta Genomics (ROSG) Appoints Former J&J (JNJ) Exec Roy Davis to Its Board
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics (Nasdaq: ROSG), announced the appointment of Roy N. Davis (age 65) to its Board of Directors. With this addition the Company's Board has six members. Mr. Davis had been with Johnson & Johnson (NYSE: JNJ) for 27 years prior to his retirement this past January.
Most recently, from January 2008 through January 2012 Mr. Davis was President, Johnson & Johnson Development Corporation, J&J's wholly owned ventures group, and Vice President of Corporate Development for all of J&J. In these roles Mr. Davis was responsible for acquisition and licensing in areas outside of current J&J business sectors, venture capital investing on behalf of J&J and management of J&J's wholly owned ventures. These efforts focused on developing new companies for J&J that offer transformational health care solutions.
Most recently, from January 2008 through January 2012 Mr. Davis was President, Johnson & Johnson Development Corporation, J&J's wholly owned ventures group, and Vice President of Corporate Development for all of J&J. In these roles Mr. Davis was responsible for acquisition and licensing in areas outside of current J&J business sectors, venture capital investing on behalf of J&J and management of J&J's wholly owned ventures. These efforts focused on developing new companies for J&J that offer transformational health care solutions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Balfour Beatty names Sarah Brand VP of Tampa buildings ops
- Ingredion names Diego Reynoso as CFO, effective October 2026
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
